Investigating the impact of a toxin on heart and blood vessel function during acute kidney injury
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
This study is testing how a harmful toxin that builds up during kidney injury might affect heart and blood vessel function in people with acute kidney injury.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 105 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Trial ID | NCT05659589 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the relationship between the accumulation of the uremic toxin Indoxyl Sulfate and cardiovascular complications in patients experiencing acute kidney injury (AKI). It focuses on patients hospitalized with moderate to severe AKI, assessing how high levels of this toxin may lead to early vascular and cardiac dysfunction, measured through pulse wave velocity. By analyzing blood samples, the study seeks to uncover the mechanisms linking AKI and cardiovascular risks, which remain poorly understood despite existing associations.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old hospitalized with moderate to severe acute kidney injury without the need for dialysis.
Not a fit: Patients with severe chronic kidney disease, those with specific types of acute kidney injury, or significant cardiovascular issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in patients with acute kidney injury.
How similar studies have performed: While some studies have linked acute kidney injury to cardiovascular risks, the specific investigation of Indoxyl Sulfate's role in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years old. * Patients hospitalized in conventional hospital departments and in intensive care units of nephrology. * Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis. * AKI from functional or organic aetiology Exclusion Criteria: * Patients with severe CKD (GFR\<45ml/min/1.73 m2) or with kidney transplants. * Patients with AKI from septic or obstructive aetiology. * Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity. * Patients with sepsis or blood inflammation. * Patients with severe chronic cardia dysfunction. * Patients with arrhythmia or complete heart block. * Patients with peripheral artery occlusive disease. * Pregnancy. * Patients on palliative care.
Where this trial is running
Amiens
- Amiens hospital — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Pauline Caillard, MD
- Email: caillard.pauline@chu-amiens.fr
- Phone: 03 22 45 58 66
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.